The Food and Drug Administration and the Office for Human Research Protections (OHRP), which is housed in the Department of Health and Human Services, “should suspend studies of a dangerous drug and promptly investigate allegations that these studies are unethical and fail to comply with federal regulations that protect human subjects,” health advocacy Public Citizen said today in letters to the two agencies.
One of the studies involves children, which raises serious ethical concerns and appears to violate special federal regulations designed to protect children in research, said Michael Carome, deputy director of Public Citizen’s Health Research Group. The drug, Ilaris (canakinumab), is manufactured by Swiss drug major Novartis (NOVN: VX) and approved by the FDA only for treating a group of rare serious genetic disorders called cryopyrin-associated periodic syndromes, which cause widespread inflammation in the body.
Ilaris approved in EU, but got negative review from FDA advisory panel
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze